AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO DRUGS USED IN GOVERNMENT-SANCTIONED EXECUTIONS.

153rd General Assembly (2025-2026) Introduced by Sean Lynn and 3 co-sponsors

Delaware HB 61 would update how the state selects, procures, and regulates drugs used in government-sanctioned executions.

Introduced and Assigned to Judiciary Committee in House

Bill Summary: HB 61 (Session 153, Delaware)

Purpose and intent

Bills amends Title 16 of the Delaware Code related to the drugs used in government-sanctioned executions.

The core aim appears to address governance, procurement, standards, or oversight surrounding the specific drugs used for capital punishment at the state level.

Key provisions and changes (as introduced)

The bill is categorized under “Drugs Used in Government-Sanctioned Executions,” indicating changes to legal or regulatory framework governing these substances.

Potential areas typically addressed by such bills (based on the title) may include:

Certification and procurement requirements for execution drugs.
Oversight, reporting, and transparency obligations related to the sourcing and use of these drugs.
Restrictions or specifications on acceptable drugs, dosages, or administration protocols.
Safeguards to ensure compliance with state and federal law, medical ethics guidelines, and court rulings.

Exact statutory text and specific provisions are not provided in the summary, but it is reasonable to expect amendments that update or clarify how the state acquires and uses execution-related pharmaceuticals.

Who or what would be affected

State agencies involved in executing sentences (likely the Department of Corrections or equivalent agency responsible for capital punishment procedures).

Medical professionals or licensed practitioners who would be involved in or oversee the administration of execution drugs.

Suppliers and pharmaceutical manufacturers or distributors that contract with the state for execution drugs.

The broader public interest, including inmate rights, judicial processes, and transparency/ethical considerations around capital punishment.

Procedural and timeline aspects

Introduction and assignment: The bill was introduced on 2025-03-06 and assigned to the Judiciary Committee in the House.

No further action or committee vote history is provided in this summary. Details on committee hearings, amendments, or floor votes would be essential to track for understanding the bill’s progression toward potential enactment.

Practical implications and considerations

If enacted, the bill could modify how Delaware selects, procures, and governs the use of drugs in executions, potentially affecting timeliness, cost, privacy, and compliance with evolving medical ethics standards.

Stakeholders to monitor include advocacy groups on both sides of the death penalty debate, medical associations, pharmaceutical suppliers, and state fiscal offices due to any cost or procurement implications.

If you’d like, I can tailor this summary to include any available text from the bill, compare it to existing Delaware law on capital punishment drugs, or outline a potential timeline for legislative progression based on typical Delaware House procedures.